Drug intelligence / Profile preview

ME010

Development stage: Preclinical
Lead developer: Letolab
Modality: Recombinant Proteins and Enzymes

Overview

ME010 is a recombinant protein therapeutic being developed by Letolab for the treatment of Growth Hormone Deficiency (GHD). It functions as an agonist of the growth hormone receptor (GHR), designed to mimic the physiological activity of endogenous growth hormone to stimulate growth and regulate metabolic processes. By targeting the GHR, ME010 aims to provide a replacement therapy for patients who lack sufficient natural growth hormone production. As of the current pipeline status, the drug is in the IND-enabling phase of development.

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on ME010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME010.

Explore the full profile